{"id":"W4393184830","doi":"10.1182/bloodadvances.2023011030","title":"Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; Jewish General Hospital","funders":"National Cancer Institute; Incyte; BeiGene; Genentech; AstraZeneca; Celgene; Seagen; Gilead Sciences; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Brentuximab vedotin; Nivolumab; Lymphoma; Medicine; Oncology; Internal medicine; Refractory (planetary science); CD30; Immunotherapy; Biology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003043074,0.0004413316,0.001016435,0.0002521182,0.0005418313,0.0004539175,0.0004211251,0.0005947225,0.002988156],"category_scores_gemma":[0.0003361955,0.0001616808,0.0005663659,0.0002022762,0.0002787061,0.000445577,0.0002246941,0.001326601,0.0007260574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007622994,"about_ca_system_score_gemma":0.0006062409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001454103,"about_ca_topic_score_gemma":0.004187389,"domain_scores_codex":[0.9998864,0.00002562567,0.00001141096,0.00001651664,0.00001219281,0.00004788812],"domain_scores_gemma":[0.9998785,0.00002641817,0.000009782052,0.00001022141,0.000006340729,0.00006877407],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.06342962,0.005051568,0.04124922,0.002148525,0.001302141,0.1178896,0.0004745129,0.004758822,0.05183841,0.001857593,0.02921047,0.6807896],"study_design_scores_gemma":[0.05375634,0.09286881,0.3664955,0.001324381,0.0035627,0.2523592,0.001112671,0.02788673,0.03131662,0.004370418,0.1646683,0.0002782671],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9502334,0.02461313,0.001084988,0.00308703,0.00103252,0.000427661,0.0004056211,0.0002918777,0.01882377],"genre_scores_gemma":[0.9917316,0.002686662,0.0006431839,0.0009229758,0.0002592699,0.00007800121,0.0002842251,0.00002394453,0.003370128],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002988156,"threshold_uncertainty_score":0.009996414,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01127234975270641,"score_gpt":0.2798334425537646,"score_spread":0.2685610928010582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}